Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank(The Netherlands Cancer Institute), Elisa A. Rozeman(The Netherlands Cancer Institute), Lorenzo F. Fanchi(The Netherlands Cancer Institute), Karolina Sikorska(The Netherlands Cancer Institute), B. van de Wiel(The Netherlands Cancer Institute), Pia Kvistborg(The Netherlands Cancer Institute), Oscar Krijgsman(The Netherlands Cancer Institute), Marlous van den Braber(The Netherlands Cancer Institute), Daisy Philips(The Netherlands Cancer Institute), Annegien Broeks(The Netherlands Cancer Institute), Johannes V. van Thienen(The Netherlands Cancer Institute), Henk Mallo(The Netherlands Cancer Institute), S. Adriaansz(The Netherlands Cancer Institute), Sylvia ter Meulen(The Netherlands Cancer Institute), Loes M. Pronk(The Netherlands Cancer Institute), Lindsay G. Grijpink-Ongering(The Netherlands Cancer Institute), Annemarie Bruining(The Netherlands Cancer Institute), Rachel M. Gittelman(Adaptive Biotechnologies (United States)), Sarah Warren(Nanostring Technologies (United States)), Harm van Tinteren(The Netherlands Cancer Institute), Daniel S. Peeper(The Netherlands Cancer Institute), John B.A.G. Haanen(The Netherlands Cancer Institute), Alexander C. J. van Akkooi(The Netherlands Cancer Institute), Ton N. Schumacher(The Netherlands Cancer Institute)
Nature Medicine
October 4, 2018
Cited by 852

Abstract


Related Papers

No related papers found

Powered by citation graph analysis